Literature DB >> 21041050

Serial MRI changes in a patient with infantile Alexander disease and prolonged survival.

Takashi Shiihara1, Toru Yoneda, Ikuko Mizuta, Tomokatsu Yoshida, Masanori Nakagawa, Nobuzo Shimizu.   

Abstract

Alexander disease is a major entity of leukodystrophy; magnetic resonance imaging (MRI) studies of the brain typically show extensive changes in the cerebral white matter with frontal predominance. Heterozygous missense mutations of GFAP are thought to be sufficient for the molecular diagnosis, which has widened the Alexander disease entity beyond the classical one. We report the patient, a 16-year-old Japanese boy, with infantile-onset Alexander disease, showing striking MRI findings; extreme white matter loss of cerebrum through cerebellum, severe atrophy of basal ganglia, cerebellum, brain stem, and cervical spinal cord. Molecular analysis showed a heterozygous mutation R239L (c.730G>T) in GFAP. A relative long disease course, over 15years, with the help of mechanical ventilation revealed the striking MRI progression.
Copyright © 2010 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21041050     DOI: 10.1016/j.braindev.2010.10.007

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  2 in total

1.  Alexander Disease Mutations Produce Cells with Coexpression of Glial Fibrillary Acidic Protein and NG2 in Neurosphere Cultures and Inhibit Differentiation into Mature Oligodendrocytes.

Authors:  Ulises Gómez-Pinedo; Maria Salomé Sirerol-Piquer; María Durán-Moreno; José Manuel García-Verdugo; Jorge Matias-Guiu
Journal:  Front Neurol       Date:  2017-06-06       Impact factor: 4.003

2.  Infantile-onset Alexander disease in a child with long-term follow-up by serial magnetic resonance imaging: a case report.

Authors:  Fumiko Nishibayashi; Miho Kawashima; Yoshiaki Katada; Nobuyuki Murakami; Miwako Nozaki
Journal:  J Med Case Rep       Date:  2013-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.